NanoViricides wins DRC ethics nod for NV-387 Ebola trial
• NanoViricides has received approval from the National Ethics Committee in the Democratic Republic of Congo to conduct a Phase II trial of NV-387. • The trial will test the efficacy of NV-387 oral gummies specifically designed to treat the Bundibugyo strain of the Ebola virus. • The company is now preparing the necessary regulatory filings for ACOREP to move the clinical study forward.
stocktitan.net